These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26945756)
1. Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice. Bonnet N; Gerbaix M; Ominsky M; Ammann P; Kostenuik PJ; Ferrari SL Calcif Tissue Int; 2016 Jul; 99(1):99-109. PubMed ID: 26945756 [TBL] [Abstract][Full Text] [Related]
2. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676 [TBL] [Abstract][Full Text] [Related]
3. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Lloyd SA; Yuan YY; Kostenuik PJ; Ominsky MS; Lau AG; Morony S; Stolina M; Asuncion FJ; Bateman TA Calcif Tissue Int; 2008 May; 82(5):361-72. PubMed ID: 18465074 [TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Ulrich-Vinther M; Andreassen TT Calcif Tissue Int; 2005 Apr; 76(4):280-6. PubMed ID: 15812581 [TBL] [Abstract][Full Text] [Related]
5. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Ominsky MS; Kostenuik PJ; Cranmer P; Smith SY; Atkinson JE Osteoporos Int; 2007 Aug; 18(8):1073-82. PubMed ID: 17384898 [TBL] [Abstract][Full Text] [Related]
6. Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. Bonnet N; Gineyts E; Ammann P; Conway SJ; Garnero P; Ferrari S PLoS One; 2013; 8(10):e78347. PubMed ID: 24167618 [TBL] [Abstract][Full Text] [Related]
7. The effects of strength training and raloxifene on bone health in aging ovariectomized rats. Stringhetta-Garcia CT; Singulani MP; Santos LF; Louzada MJ; Nakamune AC; Chaves-Neto AH; Rossi AC; Ervolino E; Dornelles RC Bone; 2016 Apr; 85():45-54. PubMed ID: 26812611 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202 [TBL] [Abstract][Full Text] [Related]
9. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326 [TBL] [Abstract][Full Text] [Related]
10. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011 [TBL] [Abstract][Full Text] [Related]
11. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806 [TBL] [Abstract][Full Text] [Related]
12. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia. Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811 [TBL] [Abstract][Full Text] [Related]
13. Peak bone strength is influenced by calcium intake in growing rats. Viguet-Carrin S; Hoppler M; Membrez Scalfo F; Vuichoud J; Vigo M; Offord EA; Ammann P Bone; 2014 Nov; 68():85-91. PubMed ID: 25102437 [TBL] [Abstract][Full Text] [Related]
14. Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. Ulrich-Vinther M; Schwarz EM; Pedersen FS; Søballe K; Andreassen TT Bone; 2005 Dec; 37(6):751-8. PubMed ID: 16169783 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM; J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785 [TBL] [Abstract][Full Text] [Related]
16. Role of parathyroid hormone in the mechanosensitivity of fracture healing. Gardner MJ; van der Meulen MC; Carson J; Zelken J; Ricciardi BF; Wright TM; Lane JM; Bostrom MP J Orthop Res; 2007 Nov; 25(11):1474-80. PubMed ID: 17568439 [TBL] [Abstract][Full Text] [Related]
17. Bone mineral density, chemical composition and biomechanical properties of the tibia of female rats exposed to cadmium since weaning up to skeletal maturity. Brzóska MM; Majewska K; Moniuszko-Jakoniuk J Food Chem Toxicol; 2005 Oct; 43(10):1507-19. PubMed ID: 16005137 [TBL] [Abstract][Full Text] [Related]
18. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients. Bonani M; Meyer U; Frey D; Graf N; Bischoff-Ferrari HA; Wüthrich RP Kidney Blood Press Res; 2016; 41(5):614-622. PubMed ID: 27622692 [TBL] [Abstract][Full Text] [Related]
19. The effect of feeding different sugar-sweetened beverages to growing female Sprague-Dawley rats on bone mass and strength. Tsanzi E; Light HR; Tou JC Bone; 2008 May; 42(5):960-8. PubMed ID: 18328797 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide affects the skeletal system of young rats. Kaczmarczyk-Sedlak I; Sedlak L; Rymkiewicz I Acta Pol Pharm; 2013; 70(2):323-31. PubMed ID: 23614289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]